Most Popular News Stories on OBR Daily

The ten most read articles from OBR daily in the past two weeks, updated continually:

#1: Biotech's Next Big Thing: ASCO

(TheStreet [video]) May 9, 2013 - TheStreet Sr. Columnist Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
read article »

#2: 2013 FDA Drug Approval Calendar

(TheStreet) May 21, 2013 - An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
read article »

#3: Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer

(MarketWatch) May 7, 2013 - Amgen today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival.
read article »

#4: Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug

(Bloomberg) May 15, 2013 - Bayer AG and Algeta ASA won U.S. approval for their drug to treat an advanced form of prostate cancer that doesn't respond to the standard testosterone-lowering treatments.
read article »

#5: Millennium CEO Resigns Amid Changes

(Boston Globe) May 9, 2013 - The chief executive of Millennium Pharmaceuticals in Cambridge resigned suddenly Thursday after its Japanese parent company, Takeda Pharmaceutical Co., moved to fold Millennium's big Cambridge-based cancer research unit into corporate research and development.
read article (free registration required) »

#6: Pfizer Halts Study of Lymphoma Drug Unlikely to Help Survival

(Reuters) May 20, 2013 - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
read article »

#7: Doctors' Lucrative Industry Ties

(New York Times/Well blog) May 13, 2013 - New reporting laws show how widespread gifts and payments, sometimes running into hundreds of thousands of dollars, from drug and device firms are to physicians.
read article »

#8: Novartis Drug Afinitor Significantly Extended Time Without Disease Progression in Women with HER2 Positive Advanced Breast Cancer

(Novartis) May 17, 2013 - Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced breast cancer showed that Afinitor (everolimus) tablets in combination with trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival (PFS) after prior therapy when compared to treatment with placebo plus trastuzumab and vinorelbine, meeting the study's primary endpoint.
read corporate press release »

#9: Lilly to Take $30M Charge After Relapse Cancer Drug Disappoints in Trial

(Fox Business) May 10, 2013 - Eli Lilly said Friday it will take a current-quarter charge of $30 million after its exploratory relapse cancer drug enzastaurin failed to meet expectations in a late-stage study.
read article »

#10: Drugmakers Open New Front Against Cancer with Next Generation of Experimental Drugs

(Washington Post/Bloomberg) May 13, 2013 - Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
read article (free registration required) »